Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants

Fibroblast growth factor receptor (FGFR) dysregulation is involved in a variety of tumorigenesis and development. Cholangiocarcinoma is closely related with FGFR aberrations, and pemigatinib is the first drug approved to target FGFR for the treatment of cholangiocarcinoma. Herein, we undertake bioch...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Qianmeng, Chen, Xiaojuan, Qu, Lingzhi, Guo, Ming, Wei, Hudie, Dai, Shuyan, Jiang, Longying, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814635/
https://www.ncbi.nlm.nih.gov/pubmed/36698015
http://dx.doi.org/10.1038/s42004-022-00718-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814635/
https://www.ncbi.nlm.nih.gov/pubmed/36698015
http://dx.doi.org/10.1038/s42004-022-00718-z

Ejemplares similares